错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Painful physical symptoms and antidepressant treatment outcome in depression: a systematic review and meta-analysis

  • Jia Jia Liu,
  • Xiao Huang,
  • Yan-Ping Bao,
  • Lin Lu,
  • Ping Dong,
  • Owen M. Wolkowitz,
  • John R. Kelsoe,
  • Jie Shi,
  • Ya Bin Wei

摘要

Background

Painful physical symptoms (PPS) are highly prevalent in patients with major depressive disorder (MDD). Presence of PPS in depressed patients are potentially associated with poorer antidepressant treatment outcome. We aimed to evaluate the association of baseline pain levels and antidepressant treatment outcomes.

Methods

We searched PubMed, Embase and Cochrane Library databases from inception through February 2023 based on a pre-registered protocol (PROSPERO: CRD42022381349). We included original studies that reported pretreatment pain measures in antidepressant treatment responder/remitter and non-responder/non-remitter among patients with MDD. Data extraction and quality assessment were performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses by two reviewers independently. The primary outcome was the difference of the pretreatment pain levels between antidepressant treatment responder/remitter and non-responder/non-remitter. Random-effects meta-analysis was used to calculate effect sizes (Hedge’s g) and subgroup and meta-regression analyses were used to explore sources of heterogeneity.

Results

A total of 20 studies were included. Six studies reported significantly higher baseline pain severity levels in MDD treatment non-responders (Hedge’s g = 0.32; 95% CI, 0.13–0.51; P = 0.0008). Six studies reported the presence of PPS (measured using a pain severity scale) was significantly associated with poor treatment response (OR = 1.46; 95% CI, 1.04-2.04; P = 0.028). Five studies reported significant higher baseline pain interference levels in non-responders (Hedge’s g = 0.46; 95% CI, 0.32–0.61; P < 0.0001). Four studies found significantly higher baseline pain severity levels in non-remitters (Hedge’s g = 0.27; 95% CI, 0.14–0.40; P < 0.0001). Eight studies reported the presence of PPS significantly associated with treatment non-remission (OR = 1.70; 95% CI, 1.24–2.32; P = 0.0009).

Conclusions

This study suggests that PPS are negatively associated with the antidepressant treatment outcome in patients with MDD. It is possible that better management in pain conditions when treating depression can benefit the therapeutic effects of antidepressant medication in depressed patients.